No Data
Why is Fosun Pharma privatizing Henlius at this time? | Jianzhi Research
The suspension of Henlius stocks has finally been resolved, consistent with previous market rumors: Fosun Pharma will privatize Henlius for delisting, with a privatization valuation of approximately RMB 12.4 billion. Fosun Pharma's bid for each share of Henlius is HKD 24.60, a premium of 30.6% over its pre-suspension closing price. Based on last year's net profit of CNY 546 million for Henlius, this privatization has a PE ratio of approximately 23 times. The total transaction is HKD 5.4 billion, which will use no more than HKD 3.7 billion in acquisition loans. Henlius has a total share capital of 543.5 million shares, including 163.4 million H shares and 380.1 million non-listed shares. The tenderer in this case is Fosun.
AH stocks collectively opened lower, with brokerage and baijiu sector falling, and Kweichow Moutai falling more than 2%.
On Monday, the Shanghai Composite Index opened down 0.49%, the Shenzhen Component Index fell 0.3%, and the Growth Enterprise Market fell 0.42%. The Wande total A shares fell 0.49%. Commercial aerospace and ultra-high-voltage power transmission concepts strengthened, while baijiu, brokerage, and education industries had the biggest decline. Kweichow Moutai continued to fall, down 2.7%. Hong Kong stocks opened and fell, with the Hang Seng Index down 0.52%, enn energy and galaxy ent both fell nearly 2%, and Alibaba fell more than 1%. The Hang Seng Tech Index fell 0.58%, with Weibo and Kuaishou both down more than 1%. Brilliance Chi rose nearly 15% and plans to distribute special stock dividends of HK$4.3 per share. In the A-share sector, electrical utilities once again fell, with Sichuan Mingxing Electric Power down nearly
Is the “top automotive company” about to fall from its throne?
After 18 years of being the leader of domestic auto companies, SAIC Motor Corporation's throne is about to be challenged. Recently, the sales figures for May have been released by automakers, with SAIC Motor Corporation holding the top spot with wholesale sales of 332,000 vehicles. However, the challengers are already at the doorstep, with BYD Company Limited following closely behind with a slight gap (330,500 vehicles). This new energy 'tyrant' is still attacking fiercely, and institutions predict that it is likely to surpass SAIC Motor Corporation in many aspects in the second quarter. A new king is about to be born, and the history of the domestic auto industry dominated by joint ventures will be rewritten, leaving little room for SAIC to retreat. However, SAIC Motor Corporation is not willing to accept this. Since last year, this top automaker has been hitting the accelerator.
Ah stocks opened low and went down, while apple supplier shares were strong. Shipping, metals sector continued to decline, and Kweichow Moutai rose 1%.
Consumer electronics stocks are strong, while shipping and precious metals sectors continue to decline. Baijiu sector rebounded slightly, and Kweichow Moutai rose 1% during early trading. Hong Kong stocks opened low and moved lower, with Hang Seng Tech Index falling 1%. Electric vehicle stocks led the decline, with Nio Inc dropping more than 7%, Xpeng dropping 5%, and Li Auto dropping 2%.
The Feitian series all experienced a large drop, with Moutai's stock price falling more than 3% and trading volume exceeding 10 billion yuan.
On Tuesday, the A-share baijiu sector fell across the board, with kweichow moutai falling more than 3% during the day and trading volume exceeding 10 billion yuan. Since the beginning of this year, kweichow moutai has fallen more than 9%. Prior to this, the Securities Times reported that on the day of the Dragon Boat Festival, the Feitian series fell sharply. According to information released by the No. 2 Sauce platform, from 2023-24, the original box price will drop by 5-10 yuan/bottle, and the bulk price will drop by 40 yuan/bottle in 2024; the zodiac series, the Rabbit, Tiger, and Pig years will drop by 30-50 yuan/bottle, while the Rat and Monkey years will plummet by 100-200 yuan/bottle; the other series will drop by 100 yuan per bottle for the 30-year vintage. The Securities Times cited industry sources as saying that in recent days,
Hengrui's FORM 483 is not that simple | Jianzhi Research
According to the FDA website, Hengrui's January on-site inspection has entered the OAI phase, which means that the FDA is not satisfied with the company's first-stage response and corrective actions, and has made a formal regulatory decision. However, it should be emphasized that Hengrui still has the opportunity to submit rectification measures before further regulatory measures are taken. And this on-site inspection has nothing to do with the dual AI therapy going global.